SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-154264
Filing Date
2020-05-28
Accepted
2020-05-28 16:10:48
Documents
16
Period of Report
2020-05-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d909916d8k.htm   iXBRL 8-K 43377
2 EX-1.1 d909916dex11.htm EX-1.1 242687
3 EX-4.1 d909916dex41.htm EX-4.1 63232
4 EX-5.1 d909916dex51.htm EX-5.1 12214
8 GRAPHIC g909916g0528140435922.jpg GRAPHIC 2534
  Complete submission text file 0001193125-20-154264.txt   582508

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA atra-20200526.xsd EX-101.SCH 3070
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20200526_lab.xml EX-101.LAB 18139
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20200526_pre.xml EX-101.PRE 11408
14 EXTRACTED XBRL INSTANCE DOCUMENT d909916d8k_htm.xml XML 3440
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 20921170
SIC: 2836 Biological Products, (No Diagnostic Substances)